Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Breast cancer is the most common worldwide cancer and a leading cause of cancer-related death in women.
• While survival rates have improved, advanced or metastatic breast cancer still has a low survival rate, necessitating new therapeutic strategies.
• Triple-negative breast cancer subtypes lack specific targets, emphasizing the need for novel therapeutic approaches.

Purpose of the Study:

• To review emerging intrinsic therapeutic targets for metastatic breast cancer.
• To summarize the latest developments in breast cancer immunotherapy.
• To identify new druggable targets for advanced and metastatic breast cancer.

Main Methods:

• Literature review of emerging therapeutic targets in metastatic breast cancer.
• Analysis of high-throughput approaches for identifying therapeutic targets.
• Review of current clinical trials and FDA-approved drugs targeting these pathways.

Main Results:

• Identified key therapeutic targets including CDK4/6, PI3K/AKT/mTOR, insulin/IGF1R, EGFR/HER, JAK/STAT, PARP, TROP-2, Src kinases, histone modification enzymes, growth factor receptors, androgen receptors, breast cancer stem cells, matrix metalloproteinases, and immune checkpoint proteins.
• Highlighted advancements in breast cancer immunotherapy.
• Noted that drugs targeting these pathways are either FDA-approved or in clinical trials.

Conclusions:

• Emerging intrinsic targets and immunotherapies offer new hope for treating metastatic breast cancer.
• Continued research into novel druggable targets is crucial for improving outcomes in advanced disease.
• Targeted therapies and immunotherapies are advancing treatment options for breast cancer patients.